Baird lowered the firm’s price target on Certara (CERT) to $13 from $18 and keeps a Neutral rating on the shares. The firm views recent CRO reports noting downward adjustments in pharma spending toward the end of 3Q24 as increasing risks that Certara sees more muted 4Q24 seasonality and FY25 improvement.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue